C OSBORNE to Risk Factors
This is a "connection" page, showing publications C OSBORNE has written about Risk Factors.
Connection Strength
0.041
-
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):433-9.
Score: 0.007
-
Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989 Dec; 3(4):641-52.
Score: 0.007
-
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol. 2009 Oct 20; 27(30):4973-9.
Score: 0.007
-
Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. J Am Vet Med Assoc. 2005 Feb 01; 226(3):393-400.
Score: 0.005
-
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
Score: 0.003
-
Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997 Dec 17; 89(24):1874-81.
Score: 0.003
-
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996 Nov; 14(11):3009-17.
Score: 0.003
-
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). J Natl Cancer Inst Monogr. 1992; (11):167-72.
Score: 0.002
-
Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992; (11):97-104.
Score: 0.002
-
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989 Feb 23; 320(8):485-90.
Score: 0.002